Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Lupin Ltd.
NSE: LUPIN
|
BSE: 500257
|
ISIN: INE326A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Mid-range Performer
1936.1000
-27.40
(
-1.40
%)
NSE
Sep 26, 2025
10:47 AM
Volume:
492.0K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Lupin Ltd.
09 Feb 2024
US FDA Approval
1936.10
-1.40%
Lupin (HOLD): All-round beat; margins sustain raise to HOLD
Hold:
Lupin Ltd.
by
BOB Capital Markets Ltd.
Target: 1560
Recommendation
Target
BOB Capital Markets Ltd.
Strong Q3 with EBITDA/PAT of Rs 10.2bn/Rs 6.1bn, beating consensus by 17%/42%
Lupin Ltd. has an
average target
of 2326.00 from 8 brokers.
More from Lupin Ltd.
Recommended
Market trades lower, the US announces 100% tariff on patented drug imports
Trendlyne Marketwatch |
26 Sep 2025, 10:46AM
Indices at a glance: Biggest winners and losers over the past year
The Baseline |
25 Sep 2025, 12:17PM
Lupin expects normalization by September quarter
|
17 Apr 2020